COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
February 28, 2023 07:00 ET
|
COMPASS Pathways
Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET...
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
February 24, 2023 12:01 ET
|
COMPASS Pathways
LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
December 08, 2022 04:00 ET
|
COMPASS Pathways
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II...
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
November 28, 2022 16:01 ET
|
COMPASS Pathways
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022 07:00 ET
|
COMPASS Pathways
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data...
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
November 03, 2022 06:00 ET
|
COMPASS Pathways
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at week 3 Sustained response seen through week...
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
October 26, 2022 16:00 ET
|
COMPASS Pathways
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
October 12, 2022 11:00 ET
|
COMPASS Pathways
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
October 04, 2022 09:05 ET
|
COMPASS Pathways
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
September 19, 2022 16:01 ET
|
COMPASS Pathways
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...